Floatz logo

Anti-Her2 Antibody-Drug Conjugate A166

Breast Cancer

Fudan Universityantibody_drug_conjugatePhase 2Active
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
59/ 100

Competitive context

848 Active assets in the Breast Cancer cohort.

Asset / SponsorPhaseRating
Darolutamide
Vandana Abramson
Phase 2BBB
Pertuzumab
SWOG Cancer Research Network
Phase 4BB
Palbociclib
Hoffmann-La Roche
Phase 4BB
Trastuzumab Duocarmazine
Byondis B.V.
Phase 3BB
Goserelin
TerSera Therapeutics LLC
Phase 4BB

View all 50 →

Same molecule, other indications

Anti-Her2 Antibody-Drug Conjugate A166 is also rated in:

HER2 positive breast carcinomaActive
B
Indicative · Phase 3
60 / 100
View asset →
gastric adenocarcinomaDormant
CCC
Indicative · Phase 1/2
52 / 100
View asset →
tumor of salivary glandDormant
CCC
Indicative · Phase 1/2
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →